|
Jun 27
|
Organon (OGN) Stock Sinks As Market Gains: What You Should Know
|
|
Jun 26
|
5 Must-Read Analyst Questions From Organon’s Q1 Earnings Call
|
|
Jun 25
|
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
|
|
Jun 24
|
Organon (OGN) Outpaces Stock Market Gains: What You Should Know
|
|
Jun 17
|
All You Need to Know About Organon (OGN) Rating Upgrade to Buy
|
|
Jun 17
|
OGN or DOCS: Which Is the Better Value Stock Right Now?
|
|
May 27
|
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
|
|
May 9
|
CEO & Director of Organon Picks Up 14% More Stock
|
|
May 7
|
Organon (NYSE:OGN) Reports Decreased Earnings Affecting Investor Sentiment
|
|
May 7
|
Organon & Co. (NYSE:OGN) Goes Ex-Dividend Soon
|
|
May 2
|
Organon price target lowered to $10 from $11 at BofA
|
|
Apr 2
|
Why Organon (OGN) Could Beat Earnings Estimates Again
|
|
Apr 1
|
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
|
|
Feb 15
|
Organon Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 13
|
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
|
|
Jan 28
|
An excellent week for Organon & Co.'s (NYSE:OGN) institutional owners who own 83% as one-year returns inch higher
|
|
Jan 23
|
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025
|
|
Oct 9
|
Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Oct 9
|
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
|
|
Oct 8
|
Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands
|